{"prompt": "['Novartis', 'Confidential', 'Page 62', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', 'is requested by a regulatory authority, the Investigator must inform Novartis immediately that', 'this request has been made.', '13.3', 'Publication of study protocol and results', 'The protocol will be registered in a publicly accessible database such as clinicaltrials.gov and', 'as required in EudraCT. In addition, after study completion (defines as last patient last visit)', 'and finalization of the study report the results of this trial will be submitted for publication and', 'posted in a publicly accessible database of clinical trial results, such as the Novartis clinical trial', 'results website and all required Health Authority websites (e.g. Clinicaltrials.gov, EudraCT', 'etc.)', 'For details on the Novartis publication policy including authorship criteria, please refer to the', 'Novartis publication policy training materials that were provided to you at the trial Investigator', 'meetings', '13.4', 'Quality Control and Quality Assurance', 'Novartis maintains a robust Quality Management System (QMS) that includes all activities', 'involved in quality assurance and quality control, to ensure compliance with written Standard', 'Operating Procedures (SOPs) as well as applicable global/local GCP regulations and ICH', 'Guidelines.', 'Audits of Investigator sites, vendors, and Novartis systems are performed by auditors,', 'independent from those involved in conducting, monitoring or performing quality control of the', 'clinical trial. The clinical audit process uses a knowledge/risk based approach.', 'Audits are conducted to assess GCP compliance with global and local regulatory requirements,', 'protocols and internal SOPs, and are performed according to written Novartis processes', '14', 'Protocol adherence', 'This protocol defines the study objectives, the study procedures and the data to be collected on', 'study participants. Additional assessments required to ensure safety of subjects should be', 'administered as deemed necessary on a case by case basis. Under no circumstances including', 'incidental collection is an Investigator allowed to collect additional data or conduct any', 'additional procedures for any purpose involving any investigational drugs under the protocol,', 'other than the purpose of the study. If despite this interdiction prohibition, data, information,', 'observation would be incidentally collected, the Investigator shall immediately disclose it to', 'Novartis and not use it for any purpose other than the study, except for the appropriate', 'monitoring on study participants.', 'Investigators ascertain they will apply due diligence to avoid protocol deviations. If an', 'Investigator feels a protocol deviation would improve the conduct of the study this must be', 'considered a protocol amendment, and unless such an amendment is agreed upon by', 'Novartis and approved by the IRB/IEC and health authorities, where required, it cannot be', 'implemented.']['Novartis', 'Confidential', 'Page 63', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', '14.1', 'Protocol Amendments', 'Any change or addition to the protocol can only be made in a written protocol amendment that', 'must be approved by Novartis health authorities where required, and the IRB/IEC prior to', 'implementation.', 'Only amendments that are required for subject safety may be implemented immediately', 'provided the health authorities are subsequently notified by protocol amendment and the', 'reviewing IRB/IEC is notified.', 'Notwithstanding the need for approval of formal protocol amendments, the Investigator is', 'expected to take any immediate action required for the safety of any subject included in this', 'study, even if this action represents a deviation from the protocol. In such cases, Novartis should', 'be notified of this action and the IRB/IEC at the study site should be informed according to', 'local regulations.']\n\n###\n\n", "completion": "END"}